With no revenue recorded across the ten quarters and R&D reaching $53.7M in 2026Q3 against an operating loss of $62.1M, the income statement offers no margin baseline and reflects a clinical-stage cost structure dominated by research spend.
Oruka Therapeutics, Inc. (ORKA) annual income statement — 21-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 46.86M | 3.89M | 545K |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -100% | 1105.27% | 613.39% | - |
| Cost of Goods Sold | 163K | 83K | 27K | 111K | 114K | 91K | 93K | 89K | 22K | 27K | 24K | 19K | 12K | 26K | 43K | 2.92M | 338K | 0 | 0 | 2.34M | 3.18M | 57.78M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5% | 81.84% | 10601.47% |
| Gross Profit | -163K | -83K | -27K | -111K | -114K | -91K | -93K | -89K | -22K | -27K | -24K | -19K | -12K | -26K | -43K | -2.92M | -338K | 0 | 0 | 44.52M | 706K | -57.23M |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 95% | 18.16% | -10501.47% |
| Gross Profit Growth % | - | -207.41% | 75.68% | 2.63% | -25.27% | 2.15% | -4.49% | -304.55% | 18.52% | -12.5% | -26.32% | -58.33% | 53.85% | 39.53% | 98.53% | -763.02% | - | - | -100% | 6205.67% | 101.23% | - |
| Operating Expenses | 182.94M | 121.97M | 88.1M | 7.18M | 9.73M | 19.24M | 9.67M | 5.72M | 8.1M | 18.68M | 16.59M | 11.44M | 9.68M | 6.91M | 4.28M | 4.44M | 8.84M | 22.39M | 19.27M | 61.07M | 141.28M | 15.8M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 130.33% | 3633.74% | 2900% |
| Selling, General & Admin | 29.26M | 21.33M | 13.04M | 6.17M | 5.26M | 5.41M | 4.68M | 3.89M | 3.86M | 4.61M | 4.24M | 4.37M | 4.06M | 3.99M | 3.18M | 4.44M | 5.73M | 12.38M | 8.25M | 18.42M | 27.45M | 15.8M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.31% | 706.02% | 2900% |
| Research & Development | 153.74M | 100.64M | 75.06M | 1.01M | 4.46M | 13.83M | 4.99M | 1.83M | 4.24M | 14.08M | 12.35M | 7.06M | 5.63M | 2.93M | 1.09M | 0 | 3.11M | 10.01M | 11.03M | 42.65M | 89.37M | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 91.02% | 2298.61% | - |
| Other Operating Expenses | -49K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.46M | 0 |
| Operating Income | -183.11M | -122.05M | -88.12M | -7.3M | -9.84M | -19.34M | -9.77M | -5.81M | -8.12M | -18.71M | -16.61M | -11.46M | -9.69M | -6.94M | -4.32M | -7.36M | -9.18M | -22.85M | -19.49M | -16.55M | -140.57M | -73.04M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -35.33% | -3615.59% | -13401.47% |
| Operating Income Growth % | - | -38.5% | -1107.83% | 25.86% | 49.1% | -97.98% | -67.97% | 28.38% | 56.62% | -12.63% | -45.03% | -18.18% | -39.67% | -60.69% | 41.33% | 19.77% | 59.85% | -17.22% | -17.75% | 88.22% | -92.47% | - |
| EBITDA | -182.94M | -121.97M | -88.1M | -7.18M | -9.73M | -19.24M | -9.67M | -5.72M | -8.1M | -18.68M | -16.59M | -11.44M | -9.68M | -6.91M | -4.28M | -6.76M | -8.84M | -22.39M | -19.27M | -14.21M | -137.39M | -70.37M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.33% | -3533.74% | -12911.93% |
| EBITDA Growth % | -45.34% | -38.45% | -1126.11% | 26.13% | 49.45% | -98.95% | -68.96% | 29.29% | 56.67% | -12.63% | -45.06% | -18.13% | -40.02% | -61.69% | 36.74% | 23.51% | 60.54% | -16.19% | -35.61% | 89.66% | -95.24% | - |
| D&A (Non-Cash Add-back) | 163K | 83K | 27K | 111K | 114K | 91K | 93K | 89K | 22K | 27K | 24K | 19K | 12K | 26K | 43K | 602K | 338K | 457K | 220K | 2.34M | 3.18M | 2.67M |
| EBIT | -173.64M | -105.43M | -82.26M | -5.34M | -9.93M | -19.32M | -9.74M | -5.64M | -7.96M | -18.55M | -16.44M | -11.45M | -9.69M | -6.94M | -4.32M | -5.36M | -8.41M | -11.23M | -19.25M | -12.2M | -132.19M | -70.33M |
| Net Interest Income | 30.52M | 16.63M | 4.39M | 1.96M | 675K | 0 | -9K | -7K | 0 | 0 | 169K | 14K | 7K | 5K | -1K | -3K | 755K | 32K | 62K | 6.59M | 7.8M | 1.43M |
| Interest Income | 30.52M | 16.63M | 5.86M | 1.96M | 675K | 0 | 0 | 0 | 0 | 0 | 169K | 14K | 7K | 5K | 2K | 2K | 763K | 217K | 240K | 6.69M | 8.38M | 2.43M |
| Interest Expense | 0 | 0 | 1.47M | 0 | 0 | 0 | 9K | 7K | 0 | 0 | 0 | 0 | 0 | 0 | 3K | 5K | 8K | 185K | 178K | 103K | 588K | 1M |
| Other Income/Expense | 30.53M | 16.62M | 4.4M | 1.96M | -85K | 13K | 19K | 165K | 154K | 161K | 169K | 10K | 4K | 1K | -1K | 2M | 755K | 11.43M | 62K | 4.25M | 7.8M | 1.43M |
| Pretax Income | -152.57M | -105.43M | -83.72M | -5.34M | -9.93M | -19.32M | -9.75M | -5.65M | -7.96M | -18.55M | -16.44M | -11.45M | -9.69M | -6.94M | -4.32M | -5.36M | -8.42M | -11.42M | -19.43M | -12.3M | -132.78M | -71.61M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.25% | -3415.05% | -13139.63% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -9K | -167K | -31K | -61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.28M | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0.09% | 2.96% | 0.39% | 0.33% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 19.98% | 0% | 0% | 0% | 0% |
| Net Income | -152.57M | -105.43M | -83.72M | -5.34M | -9.93M | -19.32M | -9.74M | -5.48M | -7.93M | -18.49M | -16.44M | -11.45M | -9.69M | -6.94M | -4.32M | -5.36M | -8.42M | -9.14M | -19.43M | -12.3M | -132.78M | -71.61M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.25% | -3415.05% | -13139.63% |
| Net Income Growth % | -39.67% | -25.93% | -1468.16% | 46.21% | 48.63% | -98.42% | -77.64% | 30.9% | 57.1% | -12.44% | -43.68% | -18.12% | -39.63% | -60.62% | 19.46% | 36.29% | 7.86% | 52.97% | -57.96% | 90.74% | -85.41% | - |
| Net Income (Continuing) | -152.57M | -105.43M | -83.72M | -5.34M | -9.93M | -19.32M | -9.74M | -5.48M | -7.93M | -18.49M | -16.44M | -11.45M | -9.69M | -6.94M | -4.32M | -5.36M | -8.42M | -9.14M | -19.43M | -12.3M | -132.78M | -71.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.13 | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 | -49.79 | -123.73 | -382.87 | -390.96 | -393.12 | -710.64 | -1572.48 | -2933.25 | -4808.16 | -8981.28 | -12882.00 | -999999.00 | -41731.00 | -468115.00 | -313891.00 |
| EPS Growth % | 27.19% | 53.71% | -12.39% | 46.31% | 50.42% | -98.57% | 83.13% | 59.76% | 67.68% | 2.07% | 0.55% | 44.68% | 54.81% | 46.39% | 38.99% | 46.46% | 30.28% | 99.72% | -11082.66% | 91.09% | -49.13% | - |
| EPS (Basic) | - | -2.31 | -4.99 | -4.44 | -8.27 | -16.68 | -8.40 | -49.79 | -123.73 | -382.87 | -390.96 | -393.12 | -710.64 | -1572.48 | -2933.25 | -4808.16 | -8981.28 | -12882.00 | -999999.00 | -41731.00 | -468115.00 | -313891.00 |
| Diluted Shares Outstanding | 71.59M | 45.61M | 16.79M | 14.42M | 14.41M | 13.9M | 4.71M | 110.1K | 64.11K | 48.29K | 41.98K | 29.12K | 13.56K | 5.71K | 1.47K | 1.11K | 938 | 782 | 4 | 294 | 284 | 228 |
| Basic Shares Outstanding | 71.59M | 45.61M | 16.79M | 14.42M | 14.41M | 13.9M | 4.71M | 110.1K | 64.11K | 48.29K | 41.98K | 29.12K | 13.56K | 5.71K | 1.47K | 1.11K | 938 | 782 | 4 | 294 | 284 | 228 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ORKA stock.
For fiscal year 2025, Oruka Therapeutics, Inc. (ORKA) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.5M in 2005.
Oruka Therapeutics, Inc. (ORKA) reported a net loss of $105.4M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Dilutive financing dependence risk
Pre-Revenue Status Defines Growth Profile
Based on reported figures, ORKA recorded no revenue across the ten quarters provided, so a traditional growth rate cannot be calculated and top-line trajectory is effectively data unavailable for analysis.
The income statement shows zero revenue throughout the supplied history, with the only line items being operating expenses and a small cost of revenue entry in 2025Q4 and 2026Q1-Q3. The absence of revenue means growth investors should focus instead on R&D progression and clinical milestones rather than sales momentum. Any future revenue trajectory remains speculative and warrants further investigation once commercialization timelines become clearer.
Expense Growth Outpacing Any Operating Scale
As reported in financial statements, ORKA's R&D expense climbed from $18.7M in 2024Q2 to $53.7M in 2026Q3, while SG&A rose from $2.8M to $8.4M over the same period, indicating expanding fixed-cost intensity without offsetting income.
Operating loss widened from $21.5M to $62.1M across the window, reflecting spending that scales with clinical activity rather than revenue. Because there is no gross profit base to leverage, the cost structure behaves as pure burn, and the conventional operating leverage framework does not apply. Investors should monitor whether R&D intensity moderates as trials mature or continues to accelerate.
Net Loss Shaped by Non-Cash Compensation
Based on reported figures, stock-based compensation appeared in several quarters, including $9.1M in 2026Q3 and $10.2M in 2025Q3, which may partially account for the gap between operating and net loss trends.
The reported net loss tracks operating loss closely, with net income consistently slightly less negative than operating income in some periods and more negative in others, suggesting non-operating items are modest. Stock-based compensation is a material component of reported expense and may understate the cash cost of retaining scientific talent. Reported EPS of -0.63 in 2026Q3 versus -0.54 in 2025Q4 also reflects share count changes that warrant monitoring for dilution effects.
R&D Dominates a Clinical-Stage Cost Base
According to recent SEC filings, ORKA's R&D line accounts for the overwhelming majority of total operating expense, with $53.7M of R&D against $8.4M of SG&A in the latest quarter, a ratio of roughly 86 percent to 14 percent.
This cost mix is characteristic of a clinical-stage biologics developer advancing ORKA-001 through trials, where patient recruitment and CMC activities drive spending. The SG&A base has grown more slowly than R&D, which may indicate reasonable overhead discipline during the build-out phase. Internal allocation between programs is not transparent in the supplied data, so program-level efficiency cannot be assessed.
Runway Risk Overshadows Clinical Progress
Based on reported figures, the quarterly operating loss of $62.1M in 2026Q3 compares against reported cash of roughly $46.9M, suggesting a funding gap that may require further capital raises before late-stage milestones.
If quarterly burn persists near the latest run rate, the reported cash balance would cover less than one quarter of operating losses, a dynamic that investors should weigh heavily against the pro-forma effects of the ARCA merger and any PIPE proceeds not visible in this snapshot. Dilution risk is therefore the central counter-argument, as financing may occur at valuations that absorb much of the platform premium the market appears to assign. The thesis could be undermined if clinical data slips or financing terms deteriorate.